Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:activities |
gram-positive bacteria
atypical bacteria some gram-negative bacteria |
| gptkbp:administered_by |
gptkb:cream
oral tablet intravenous injection |
| gptkbp:available_in |
liquid form
capsule form tablet form suspension form injectable form |
| gptkbp:available_on |
erythromycin ethylsuccinate
erythromycin lactobionate erythromycin stearate |
| gptkbp:brand |
Erythrocin
Erythromycin base Ilosone |
| gptkbp:category |
B
|
| gptkbp:class |
macrolide antibiotic
|
| gptkbp:contraindication |
gptkb:myasthenia_gravis
liver disease |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:discovered_by |
gptkb:1952
|
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
erythromycin
|
| gptkbp:interacts_with |
gptkb:carbamazepine
gptkb:theophylline gptkb:warfarin |
| gptkbp:is_effective_against |
fungal infections
viral infections most gram-negative bacteria |
| gptkbp:lifespan |
1.5 hours
|
| gptkbp:mechanism_of_action |
inhibits protein synthesis
|
| gptkbp:metabolism |
liver
|
| gptkbp:produced_by |
Saccharopolyspora erythraea
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea abdominal pain vomiting diarrhea rash loss of appetite |
| gptkbp:targets |
bacterial ribosomes
|
| gptkbp:used_for |
bacterial infections
|
| gptkbp:used_in |
gptkb:Skin
gptkb:pneumonia whooping cough skin infections strep throat chlamydia infections gastric emptying studies |
| gptkbp:bfsParent |
gptkb:CYP3_A4
|
| gptkbp:bfsLayer |
4
|